KDIGO 2012: acute kidney injury
International KDIGO Current
KDIGO Clinical Practice Guideline for Acute Kidney Injury
Kidney Disease: Improving Global Outcomes AKI Work Group. Kidney Int Suppl. 2012;2:1–138
Summary checked against the source: 2026-11
Still the current KDIGO AKI guideline (an update is in progress). Grades: 1/2 with evidence A–D; NG = not graded. Pages are from Kidney International Supplements 2012, volume 2.
At a glance
- AKI = creatinine up ≥0.3 mg/dL within 48 h, or to ≥1.5 × baseline within 7 days, or urine <0.5 mL/kg/h for 6 h. [NG · p. 8]
- Stage 1–3 by creatinine or urine output, whichever is worse. [NG · p. 8]
- Isotonic crystalloid, not colloid, for volume expansion (unless haemorrhagic shock); vasopressors with fluids in vasomotor shock. [2B, 1C · p. 8]
- Don't use diuretics to prevent or treat AKI (except for fluid overload); no low-dose dopamine. [1B, 2C, 1A · p. 9]
- Contrast AKI: IV saline or bicarbonate volume expansion and low- or iso-osmolar contrast at the lowest dose. [1A, 1B · p. 10]
- Start dialysis for life-threatening fluid, electrolyte or acid–base problems, and otherwise on the whole clinical picture rather than a single urea or creatinine. [NG · p. 10]
- Review at 3 months for recovery or new or worse CKD. [NG · p. 8]
Definition and staging
| Stage | Serum creatinine | Urine output |
|---|---|---|
| 1 | 1.5–1.9 × baseline, or rise ≥0.3 mg/dL (≥26.5 µmol/L) | <0.5 mL/kg/h for 6–12 h |
| 2 | 2.0–2.9 × baseline | <0.5 mL/kg/h for ≥12 h |
| 3 | 3.0 × baseline, or creatinine ≥4.0 mg/dL (≥353.6 µmol/L), or starting RRT, or (under 18) eGFR <35 | <0.3 mL/kg/h for ≥24 h, or anuria ≥12 h |
Adapted from KDIGO 2012 Table 2 [p. 8]
- Stratify everyone by susceptibility and exposure to AKI. [1B · p. 8]
- In those at risk, monitor creatinine and urine output; find the cause promptly, especially reversible ones. [NG · p. 8]
Stage-based management
| Action | High risk | Stage 1 | Stage 2 | Stage 3 |
|---|---|---|---|---|
| Stop all nephrotoxic drugs if possible | ✓ | ✓ | ✓ | ✓ |
| Ensure volume status and perfusion pressure | ✓ | ✓ | ✓ | ✓ |
| Consider functional haemodynamic monitoring | ✓ | ✓ | ✓ | ✓ |
| Monitor creatinine and urine output | ✓ | ✓ | ✓ | ✓ |
| Avoid hyperglycaemia | ✓ | ✓ | ✓ | ✓ |
| Consider alternatives to radiocontrast | ✓ | ✓ | ✓ | ✓ |
| Non-invasive diagnostic work-up | ✓ | ✓ | ✓ | |
| Consider invasive diagnostic work-up | ✓ | ✓ | ✓ | |
| Check drug doses | ✓ | ✓ | ||
| Consider RRT | ✓ | ✓ | ||
| Consider ICU admission | ✓ | ✓ | ||
| Avoid subclavian catheters if possible | ✓ |
Priority rises with each stage. Adapted from KDIGO 2012 Figure 4 [p. 9]
Prevention and treatment
Recommended (grade 1) [p. 8–10]
- Vasopressors with fluids in vasomotor shock. [1C]
- No diuretics to prevent AKI. [1B]
- No low-dose dopamine. [1A]
- No recombinant IGF-1. [1B]
- No NAC to prevent AKI after surgery. [1A]
- Aminoglycoside levels if multiple daily dosing lasts >24 h. [1A]
- Azoles or echinocandins rather than conventional amphotericin B when equally effective. [1A]
Suggested (grade 2) [p. 8–9]
- Isotonic crystalloids rather than albumin or starch for initial volume expansion, unless there's haemorrhagic shock. [2B]
- Protocol-based haemodynamic and oxygenation targets perioperatively in high-risk patients and in septic shock. [2C]
- Critically ill: glucose 110–149 mg/dL (6.1–8.3 mmol/L) with insulin. [2C]
- Energy 20–30 kcal/kg/day, enteral preferred. Don't restrict protein to delay dialysis: 0.8–1.0 g/kg/day without RRT, 1.0–1.5 on RRT, up to 1.7 on CRRT or if hypercatabolic. [2C, 2D]
- Diuretics only for volume overload. [2C]
- Avoid aminoglycosides if there's a less nephrotoxic alternative; give once daily; topical or local routes where possible. [2A, 2B]
- Lipid amphotericin B over conventional. [2A]
- Not fenoldopam or ANP; no NAC in hypotensive critically ill patients; off-pump CABG not chosen just to protect the kidneys. [2C, 2D]
Contrast-induced AKI
| Statement | Grade |
|---|---|
| Assess risk and check kidney function before iodinated contrast; consider other imaging if at risk | NG |
| Lowest possible dose | NG |
| Iso- or low-osmolar contrast, not high-osmolar | 1B |
| IV isotonic saline or sodium bicarbonate volume expansion | 1A |
| Oral fluids alone are not enough | 1C |
| Oral NAC with IV crystalloid | 2D |
| No theophylline; no fenoldopam | 2C; 1B |
| No prophylactic dialysis to remove contrast | 2C |
Adapted from KDIGO 2012 section 4 [p. 10]
Dialysis in AKI
| Area | Guidance | Grade |
|---|---|---|
| When to start | Emergently for life-threatening fluid, electrolyte or acid–base changes; otherwise consider the whole picture and trends | NG |
| When to stop | When kidney function is adequate or RRT no longer fits goals of care. Don't use diuretics to hasten recovery | NG; 2B |
| Anticoagulation | Use it unless bleeding risk, coagulopathy or already anticoagulated | 1B |
| Intermittent RRT: heparin (UFH or LMWH) | 1C | |
| CRRT: regional citrate rather than heparin | 2B | |
| HIT: stop all heparin; argatroban or a factor Xa inhibitor | 1A | |
| Access | Uncuffed, non-tunnelled catheter; vein preference right jugular → femoral → left jugular → subclavian | 2D; NG |
| Ultrasound guidance; chest X-ray before using a jugular or subclavian line | 1A; 1B | |
| Modality | Intermittent and continuous are complementary. CRRT for haemodynamic instability and raised intracranial pressure | 2B |
| Buffer | Bicarbonate rather than lactate, especially in shock | 1B |
| Dose | Kt/V 3.9 per week (intermittent); effluent 20–25 mL/kg/h (CRRT) | 1A |
Adapted from KDIGO 2012 section 5 [p. 10–12]
Clinical pearls
- 0.3 in 48 h, 1.5× in 7 days, 0.5 mL/kg/h for 6 h.
- Stage 3: 3× baseline, creatinine ≥4 mg/dL, RRT, <0.3 mL/kg/h for 24 h or anuria for 12 h.
- AEIOU for urgent dialysis: Acidosis, Electrolytes (K⁺), Intoxication, Overload, Uraemia (pericarditis, encephalopathy).
- Furosemide, dopamine and NAC don't protect the kidneys.
- Contrast: IV saline, low-osmolar contrast, lowest dose.
Classes and levels of evidence
How KDIGO AKI 2012 grades its recommendations. Adapted from KDIGO AKI 2012 grading system [p. 1–138]. Hover over any class or level cited on this page to see what it means.
| Grade | Meaning | Wording used |
|---|---|---|
| 1A | Level 1, strong: we recommend. Most people would want this course of action; quality A (high): we are confident that the true effect is close to the estimate | |
| 1B | Level 1, strong: we recommend. Most people would want this course of action; quality B (moderate): the true effect is likely close to the estimate but may be substantially different | |
| 1C | Level 1, strong: we recommend. Most people would want this course of action; quality C (low): the true effect may be substantially different | |
| 1D | Level 1, strong: we recommend. Most people would want this course of action; quality D (very low): the estimate is very uncertain and often far from the truth | |
| 2A | Level 2, weak: we suggest. Most people would want it, but many would not; quality A (high): we are confident that the true effect is close to the estimate | |
| 2B | Level 2, weak: we suggest. Most people would want it, but many would not; quality B (moderate): the true effect is likely close to the estimate but may be substantially different | |
| 2C | Level 2, weak: we suggest. Most people would want it, but many would not; quality C (low): the true effect may be substantially different | |
| 2D | Level 2, weak: we suggest. Most people would want it, but many would not; quality D (very low): the estimate is very uncertain and often far from the truth | |
| Practice point | Ungraded expert advice where a systematic review was not done | |
| Not graded | Ungraded statement based on common sense, or on a topic with no basis for grading evidence |
KDIGO grades each recommendation by strength (1 = "we recommend", 2 = "we suggest") and quality of evidence (A high, B moderate, C low, D very low), written together as 1B, 2C and so on. Practice points (PP) are ungraded expert advice where no systematic review was done. Older KDIGO guidelines also have "Not Graded" statements.